Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 4/20 | 0.54 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.54 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | PAM | P19021 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6188957 | 1.00 | GRIK1 (0.54) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL27989732 | 0.91 | GRIK1 (0.62) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL27689553 | 0.91 | GRIK1 (0.62) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL7254441 | 0.85 | HTR2A (0.46) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL6192213 | 0.85 | HTR2A (0.46) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL9620462 | 0.84 | MMP8 (0.50) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL9620464 | 0.84 | MMP8 (0.50) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL3020746 | 0.84 | GRIK1 (0.59) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL3020748 | 0.84 | GRIK1 (0.59) | GRIK1GRIK2HTR2APAMGLA | |
| SCHEMBL13235939 | 0.82 | HTR2A (0.58) | GRIK1GRIK2HTR2APAMGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1347978-B1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES AS PDE II-INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-08-31 | — | — | EP | disclosed |
| EP-1347978-A1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES AS PDE II-INHIBITORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-6573263-B2 | For improving perception, concentration power, learning power and/ or memory power | BAYER AKTIENGESELLSCHAFT (DE) | 2003-06-03 | — | — | US | disclosed |
| US-20020198377-A1 | Substituted imidazotriazinones | BAYER AKTIENGESELLSCHAFT (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002050078-A1 | NOVEL SUBSTITUTED IMIDAZOTRIAZINONES AS PDE II-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198377-A1 | Substituted imidazotriazinones | CAMK4, ITPR1, KCNJ5 | GRIK1 67/4885GRIK2 47/4885HTR2A 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.